BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $407,952,821 | -15.5% | 10,833,312 | +1.9% | 0.05% | -14.0% |
| Q2 2023 | $482,991,075 | +33.1% | 10,629,326 | +18.5% | 0.06% | +21.3% |
| Q1 2023 | $362,919,340 | +80965.1% | 8,971,166 | +1.9% | 0.05% | -25.4% |
| Q4 2022 | $447,689 | -99.9% | 8,800,953 | -3.5% | 0.06% | -14.9% |
| Q3 2022 | $490,572,000 | -15.0% | 9,118,883 | +1.3% | 0.07% | -12.9% |
| Q2 2022 | $577,305,000 | -13.7% | 9,005,579 | +4.1% | 0.08% | +1.2% |
| Q1 2022 | $669,268,000 | -10.3% | 8,653,941 | -0.8% | 0.08% | -6.7% |
| Q4 2021 | $746,523,000 | +13.8% | 8,719,597 | +6.6% | 0.09% | +2.3% |
| Q3 2021 | $656,037,000 | +5.8% | 8,179,415 | +5.8% | 0.09% | +3.5% |
| Q2 2021 | $620,185,000 | +1.4% | 7,728,860 | +6.2% | 0.08% | -9.6% |
| Q1 2021 | $611,791,000 | +6.2% | 7,277,047 | +1.0% | 0.09% | -3.1% |
| Q4 2020 | $576,224,000 | +1.5% | 7,202,680 | +1.8% | 0.10% | -12.6% |
| Q3 2020 | $567,568,000 | -7.1% | 7,074,081 | -0.5% | 0.11% | -15.3% |
| Q2 2020 | $610,633,000 | +8.1% | 7,107,271 | +2.0% | 0.13% | -10.9% |
| Q1 2020 | $564,651,000 | -53.1% | 6,970,015 | -51.7% | 0.15% | +16.7% |
| Q4 2019 | $1,202,882,000 | +97.6% | 14,417,156 | +106.8% | 0.13% | -11.3% |
| Q3 2019 | $608,660,000 | +15.6% | 6,970,294 | +8.2% | 0.14% | +11.8% |
| Q2 2019 | $526,454,000 | +2.8% | 6,439,856 | +2.0% | 0.13% | -4.5% |
| Q1 2019 | $512,288,000 | -39.5% | 6,312,258 | -51.0% | 0.13% | +1.5% |
| Q4 2018 | $846,818,000 | +79.0% | 12,888,408 | +109.7% | 0.13% | -1.5% |
| Q3 2018 | $473,000,000 | +6.3% | 6,147,198 | +1.8% | 0.13% | -2.9% |
| Q2 2018 | $445,095,000 | +15.6% | 6,039,741 | +1.8% | 0.14% | +9.6% |
| Q1 2018 | $385,077,000 | +2.7% | 5,934,323 | +2.1% | 0.12% | -1.6% |
| Q4 2017 | $375,011,000 | +7.6% | 5,812,690 | +4.4% | 0.13% | -1.6% |
| Q3 2017 | $348,612,000 | +10.0% | 5,565,353 | +6.1% | 0.13% | +3.2% |
| Q2 2017 | $317,060,000 | +24.9% | 5,245,548 | +7.1% | 0.12% | +20.2% |
| Q1 2017 | $253,752,000 | +31.8% | 4,899,789 | +12.7% | 0.10% | +15.6% |
| Q4 2016 | $192,495,000 | -6.2% | 4,346,693 | +0.6% | 0.09% | -12.6% |
| Q3 2016 | $205,288,000 | +3.8% | 4,319,517 | -1.4% | 0.10% | -4.6% |
| Q2 2016 | $197,696,000 | +10.2% | 4,379,644 | +0.1% | 0.11% | +13.7% |
| Q1 2016 | $179,363,000 | +9.7% | 4,375,204 | +1.9% | 0.10% | +2.2% |
| Q4 2015 | $163,433,000 | +13.0% | 4,293,072 | -2.7% | 0.09% | +5.7% |
| Q3 2015 | $144,619,000 | -9.0% | 4,410,944 | +5.6% | 0.09% | -3.3% |
| Q2 2015 | $158,997,000 | -44.9% | 4,178,958 | -1.0% | 0.09% | -44.8% |
| Q1 2015 | $288,608,000 | -3.3% | 4,219,881 | +3.5% | 0.16% | -6.8% |
| Q4 2014 | $298,320,000 | +6.0% | 4,075,683 | +3.8% | 0.18% | -2.7% |
| Q3 2014 | $281,467,000 | -1.6% | 3,926,847 | -0.8% | 0.18% | -1.6% |
| Q2 2014 | $286,061,000 | -2.5% | 3,958,989 | -0.7% | 0.18% | -6.1% |
| Q1 2014 | $293,301,000 | +6.3% | 3,987,872 | +0.5% | 0.20% | +3.1% |
| Q4 2013 | $275,806,000 | +8.5% | 3,966,750 | +2.4% | 0.19% | -6.4% |
| Q3 2013 | $254,313,000 | -1.8% | 3,872,370 | +3.5% | 0.20% | -10.5% |
| Q2 2013 | $259,040,000 | – | 3,740,336 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |